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Abstract
Background—West Virginia (WV) residents are at high risk for polypharmacy given its
considerable chronic disease burdens. Objective: To evaluate the prevalence, correlates, outcomes,
and geographic variations of polypharmacy among WV Medicaid beneficiaries.
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Methods—In this cross-sectional study, we analyzed 2009–2010 WV Medicaid fee-for-service
(FFS) claims data for adults aged 18–64 (N=37,570). We defined polypharmacy as simultaneous
use of drugs from five or more different drug classes on a daily basis for at least 60 consecutive
days in one year. Multilevel logistic regression was used to explore the individual- and countylevel factors associated with polypharmacy. Its relationship with healthcare utilization was
assessed using negative binomial regression and logistic regression. The univariate local indicators
of spatial association method was applied to explore spatial patterns of polypharmacy in WV.
Results—The prevalence of polypharmacy among WV Medicaid beneficiaries was 44.6%. Highhigh clusters of polypharmacy were identified in southern WV, indicating counties with aboveaverage prevalence surrounded by counties with above-average prevalence. Polypharmacy was
associated with being older, female, eligible for Medicaid due to cash assistance or medical
eligibility, having any chronic conditions or more chronic conditions, and living in a county with
lower levels of education. Polypharmacy was associated with more hospitalizations, emergency
department visits, and outpatient visits, as well as higher non-drug medical expenditures.
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Conclusions—Polypharmacy was prevalent among WV Medicaid beneficiaries and was
associated with substantial healthcare utilization and expenditures. The clustering of high
prevalence of polypharmacy in southern WV may suggest targeted strategies to reduce
polypharmacy burden in these areas.
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Introduction
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Polypharmacy is conventionally regarded as the concurrent use of multiple medications. It is
associated with negative health outcomes, including drug-drug interactions, adverse drug
events, decreased medication adherence, increased risk of mortality, and increased health
care use and costs.1,2 Polypharmacy research has primarily focused on the elderly
population, whereas knowledge about the prevalence of polypharmacy and related issues in
the general adult population is still limited. However, recent studies have suggested that
multimorbidity and polypharmacy are no longer merely issues for the elderly. The
prevalence of multimorbidity among those who were 45 to 64 years old and participated in
the National Health Interview Survey increased from 24.5% in 2004 to 28.1% in 2010.3
Another study examining the 2009 Medical Expenditure Panel Survey found that the
prevalence of multimorbidity was similar in those aged 50 to 64 years (8.2%) and those ≥65
years old (9%). There was a relationship between multimorbidity and polypharmacy in both
age groups.4 Kanto et al5 also found that 15% of those who were 40 to 64 years old in 2011–
2012 had polypharmacy which was a significant increase from the 1999–2000 period
(10%).5
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On the other hand, there is no firm consensus on the definition of polypharmacy. A narrative
review of polypharmacy among elderly individuals identified 24 distinct definitions.6 These
definitions range from concurrent use of 5 or more drugs, to use of at least 1 inappropriate
drug, to use of medications that do not match a patient’s diagnosis.6 Even when studies used
a certain number of drugs to define polypharmacy, the numbers varied from 2 drugs7 to
more than 1 SD above the average number of drugs in a specific population.8 In addition, the
duration of concomitant drug use also varied ranging from 30 days to 90 days.9,10 This
inconsistency in the definition results in challenges for the measurement of polypharmacy.
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In addition, West Virginia (WV) residents are at particularly high risk for polypharmacy
because it has one of the highest chronic disease burdens in the United States.11,12 Yet, to
our knowledge, there has been no systematic examination of this critical issue in WV,
including in the Medicaid population of WV. Medicaid is a joint federal-state, public health
insurance program in the United States that mainly covers low-income individuals with
limited resources. Therefore, the purpose of this study was to estimate the prevalence of
polypharmacy by integrating the definitions used in the literature and establishing a feasible
approach for addressing this issue using administrative claims data. We also aimed to
explore the factors associated with poly-pharmacy and to evaluate the health care use, health
expenditures, and geographic variations of polypharmacy among WV Medicaid
beneficiaries.
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Methods
Study Design, Study Population, and Data Source
In this cross-sectional study, we analyzed WV Medicaid fee-for-service (FFS) claims data in
2009–2010. We included adults who were between 18 and 64 years old, alive during the
study time, and continuously enrolled in WV Medicaid’s FFS program in both 2009 and
2010. Those with dual Medicaid and Medicare eligibility and with private insurance were
excluded from the study. Appendix A shows the flowchart for obtaining the final study
population.
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The main data source was the Medicaid Analytic eXtract (MAX) data system, which
contains extensive person-level data on Medicaid beneficiaries and Medicaid health services.
We extracted data for WV Medicaid FFS enrollees from the following MAX files: person
summary file, which contains demographic and enrollment data; inpatient file, including
hospital claims; prescription drug file with pharmacy claims; and other services file, which
involves all types of services not included in the other 4 files. To assess county-level factors,
we linked the county code of each Medicaid beneficiary with the Area Health Resources File
as well as the Appalachian Regional Commission data reports. The study was approved by
WV University’s Institution Review Board.
Outcome Measures

Author Manuscript
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Polypharmacy—Our definition of polypharmacy incorporated 3 important components of
polypharmacy measures: number of drugs, simultaneous use, and duration of use. First, we
chose to use a widely accepted, standard cutoff for clinically relevant polypharmacy: the
concurrent use of 5 or more drugs from different drug classes.13–15 Drugs were identified by
the National Drug Codes and classified based on the methodology created in a previous
study.16 Second, among the 3 common measures of polypharmacy (cumulative, continuous,
and simultaneous), we chose simultaneous polypharmacy because it gives a value in
between the values of cumulative and continuous measures and can demonstrate subtle and
transient changes in medications.17 We defined simultaneous use as the sum of all drug
classes used by 1 individual daily, which was developed based on the methodology of
Fincke et al.17 Finally, we chose a consecutive interval of at least 60 days in 1 year as 1
criterion for polypharmacy definition. To summarize, by our definition, polypharmacy was
defined as simultaneous use of 5 or more drugs from different drug classes for a consecutive
interval of at least 60 days in 1 year. To allow for an 80% medication adherence rate, we also
allowed for a gap of 12 days within this interval. In other words, the individual with
polypharmacy took 5 or more drugs from different drug classes per day for at least 60 days
in 72 consecutive days in 2010.
Health Care Use and Expenditures—We examined 3 types of health care use in each
individual in 2010: inpatient hospitalization, outpatient visits, and emergency department
(ED) visits. Nondrug health care expenditures were assessed by summing up the
expenditures from inpatient services, outpatient services, home health, laboratory/X-ray, and
hospice for each eligible individual in 2010. The cost evaluation was from the payer’s
perspective.
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We examined individual- and county-level factors associated with polypharmacy, which
followed the constructs of the conceptual framework in the Andersen’s Health Behavioral
Model of Health Services Use.18,19 We measured the individual-level characteristics: (1)
predisposing factors: age group and gender; (2) enabling factors: Medicaid pathway-toeligibility indicators, including medical needs and cash assistance, and having private
insurance or not; (3) need factors: number of chronic conditions and types of chronic
conditions (physical conditions only, mental conditions only, none, or both). Chronic
conditions were identified by the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes in 2009. We utilized the strategic framework
adopted by the US Department of Health and Human Services (DHHS) for research, policy,
program, and practice20 and also added some other major mental health conditions. The final
list of chronic conditions included hypertension, congestive heart failure, coronary artery
disease, cardiac arrhythmias, hyperlipidemia, stroke, arthritis, asthma, cancer, chronic
kidney disease, chronic obstructive pulmonary disease (COPD), diabetes, hepatitis, HIV,
osteoporosis, dementia, depression, schizophrenia, substance abuse, anxiety or posttraumatic
stress disorder, and bipolar disorder (Appendix B). Environmental characteristics were
assessed by county-level factors, which included county-level metropolitan status, countylevel economic status (distressed counties refer to the lowest 10% of the US counties),21
county-level percentage of persons with less than a high school education in quartiles, and
health professional shortage area for primary care doctors.
Statistical Analysis

Author Manuscript
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We calculated polypharmacy rates for the entire final study population and for individuals
with different types of chronic conditions. Descriptive statistics of other dependent and
independent variables were calculated using means for continuous variables and frequencies
and percentages for categorical variables. We assessed bivariate associations of
polypharmacy and each factor using χ2 tests for binary and categorical variables as well as
the 2-tailed t-tests for continuous variables. To take into consideration potential clustering
effects at the county level, we used a multilevel logistic regression model to assess the
factors associated with polypharmacy. The association of polypharmacy with outpatient
visits was evaluated using a negative binomial model. We utilized logistic regressions to
assess the relationships between polypharmacy with inpatient visits and ED visits. The
impact of polypharmacy on nondrug medical expenditures was assessed using a generalized
linear model with log-link function and gamma distribution. We also used recycled
predictions to estimate absolute expenditure differences between polypharmacy and
nonpolypharmacy.22 We used STATA 14 (StataCorp LP, College Station, TX) for data
analyses.
Spatial Analysis
The aggregated county-level polypharmacy rates were displayed in choropleth maps. The
univariate local indicators of spatial association (LISA) method23 and global Moran’s I
statistics were applied to study the spatial variations of polypharmacy rates across WV. The
univariate LISA method can help identify 4 types of spatial patterns: (1) low-low cluster, (2)
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high-high cluster, (3) low-high outlier, (4) high-low outlier. A high-high cluster indicates a
county with an above-average prevalence surrounded by counties with above-average
prevalence, whereas a low-low cluster refers to a county with a below-average rate
surrounded by counties with below-average rates. The Queen contiguity weights matrix was
used to define counties sharing a border or vertex/corner with a county’s neighbors. For the
univariate LISA statistics for each observation and cluster/outlier, the significance level was
set at P <0.05. We used ArcGIS 10.4 (ESRI, Redlands, CA) for geo-mapping and GeoDa 1.8
software for the LISA method.

Results

Author Manuscript

Our analyses included a total of 37 570 WV Medicaid beneficiaries, whose characteristics
are presented in Table 1. The majority of participants were female (58.4%), middle-aged
(45–64 years old, 60.4%), eligible for Medicaid as a result of cash assistance (91.1%), and
with 1 or more chronic conditions assessed in our study (79.8%). About half of them
(51.5%) lived in nonmetropolitan areas, and 77.4% lived in primary care doctor shortage
areas. The average number of drug classes taken per person per day was 3.9.
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Based on our definition, 44.6% of adult Medicaid FFS beneficiaries in WV were classified
as having polypharmacy. Among those with polypharmacy, the average number of drug
classes taken per day was 6.7. The prevalence of polypharmacy varied among different
chronic conditions, ranging from 43.3% to 85.4%. The top 10 conditions with the highest
prevalence of polypharmacy were chronic kidney disease (85.4%), congestive heart failure
(85.1%), coronary artery disease (80.5%), diabetes (74.9%), dementia (74.4%), stroke
(73.1%), osteoporosis (71.5%), hyperlipidemia (69.8%), cardiac arrhythmias (69.2%), and
COPD (69.1%). With the exception of dementia, these conditions were also highly prevalent
generally among this nonelderly population. Patients with chronic kidney disease,
congestive heart failure, coronary artery disease, diabetes, and stroke took at least 6 drug
classes on average per day. The most prescribed drug classes at the individual level were
analgesics (74.8%) and antibiotics (68.7%), followed, in descending order, by
anticonvulsants (48.8%), antidepressants (48.4%), proton pump inhibitors (44.3%),
bronchodilators (35.4%), statins (34.5%), anxiolytics (31.9%), antihistamines (29.5%), and
angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (26.8%). Among
those with polypharmacy, 85.3% and 76.9% were prescribed analgesics and antibiotics,
respectively.
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The county-level polypharmacy rates ranged from 31.2% to 54.4% (Figure 1A). The global
Moran’s I of the county-level polypharmacy rates in WV was 0.43 (P < 0.01), indicating a
positive spatial autocorrelation (clustering patterns) of polypharmacy in WV. Accordingly, in
the univariate LISA, a large and clear high-high cluster of polypharmacy was observed in
southern WV (Figure 1B), which includes the counties of Boone, Fayette, Greenbrier,
Lincoln, Logan, Monroe, Mingo, Nicholas, Summers, Raleigh, and Wyoming. These
counties had above-average polypharmacy rates and were also surrounded by other counties
with above-average polypharmacy rates. On the other hand, 2 smaller low-low clusters were
found in northeastern W V, including Morgan and Berkeley counties.
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Table 2 displays the results of the multilevel logistic regression of polypharmacy. We found
that being older, female, eligible for Medicaid as a result of cash assistance or medical
eligibility, having any chronic condition or more chronic conditions, and living in a county
with lower levels of education were associated with a higher likelihood of polypharmacy.
Also, patients with physical conditions were more likely to have polypharmacy than those
with mental conditions (adjusted odds ratio [AOR] = 1.98; 95% CI = 1.84, 2.14). Table 3
presents the relationships between polypharmacy, health care use, and nondrug expenditures.
Those people with polypharmacy had 69% more outpatient visits than those without
polypharmacy (P < 0.01). In addition, patients with polypharmacy were more likely to have
ED visits (AOR = 1.18; 95% CI = 1.13–1.24) and inpatient visits (AOR = 1.78; 95% CI =
1.67–1.90) compared with those without polypharmacy. Polypharmacy was associated with
$4494.36 more in nondrug medical expenditures than nonpolypharmacy (coefficient = 0.69;
95% CI = 0.64–0.74; P < 0.01).
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Discussion
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The current study made a unique contribution to the limited literature of polypharmacy
research among adults younger than 65 years by estimating the prevalence of polypharmacy
among Medicaid beneficiaries in WV. By integrating various measures of prescription drugs
use—duration of use, simultaneous use, and number of drug classes, we observed that
polypharmacy was highly prevalent (44.6%) among those <65 years old, which was even
higher than the US average rate among adults >21 years of age in 2009 (25.5%) and among
the elderly population in 2010 (39.0%). Despite our strict definition, we still found such a
high prevalence in this population, suggesting a substantial burden of polypharmacy and
related issues in WV. Because this is the first study of its kind in WV, we cannot suggest
whether our study findings are consistent with those from the other literature. However, a
previous study examining the region-level variations of polypharmacy in the United States
also found that WV was located in the region with the highest prevalence of
polypharmacy.25

Author Manuscript

Not surprisingly, we found that adults with selected chronic conditions were more likely to
have polypharmacy compared with those without these selected chronic conditions. WV also
ranks among the top 10 states with the highest prevalence of many chronic conditions, such
as cardiovascular diseases, diabetes, stroke, hypertension, cancer, COPD, arthritis, and
kidney disease, as well as risk factors such as obesity, tobacco use, and physical
inactivity,11,12 which may partially explain the high burden of polypharmacy in W V.
Furthermore, given the trend of increasing polypharmacy rates among American adults over
the past 2 decades,5,24 it may be expected that the burden of polypharmacy in the WV
Medicaid population has continued to increase following the period of our study.
Consistent with the previous literature,16,26 our study showed that polypharmacy was
associated with substantial economic burden, including increased health care use and
expenditures. Based on our results in 2010, on average, 1 Medicaid beneficiary with
polypharmacy had $4494.36 more in nondrug medical expenditures. Since 2014, Medicaid
coverage in WV has been expanded to include individuals aged between 19 and 65 years old
with income limit at 133% of the federal poverty level.27 Given the chronic disease burdens
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and high polypharmacy rates in this state, it is reasonable to expect more Medicaid
beneficiaries with polypharmacy and multimorbidity, which may lead to an increase in
health care use and expenditures. Therefore, actions to control the increasing trend of these
issues are warranted in order to contain costs in the Medicaid program, which has limited
resources and a tight budget.
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To more deeply understand this issue in WV, our study further explored the county-level
geographic variations of polypharmacy prevalence and identified a high-high cluster of
polypharmacy in southern WV that included 11 counties. Almost all these 11 counties also
had higher poverty rates and lower education levels than the state as a whole.28 These
counties also had significantly higher prevalence than the WV and US averages of the
following health-related indicators: reported fair or poor general health, no leisure-time
physical activity or exercise, obesity, hypertension, cardiovascular disease, diabetes, arthritis,
and disability.11 Also, we found that the most prescribed drug classes for West Virginians
were analgesics and antibiotics. This is not surprising because WV has one of the highest
prescription rates of opioids and outpatient antibiotics in the United States.29,30 These drugs
require particular attention because of the high risk for inappropriate use and adverse drug
events leading to harms.31 Overall, our findings may be helpful for WV Medicaid policy
makers to target “hot-spot” areas and “high-risk” drugs requiring close monitoring and
regulations and to collaborate with local communities to develop and implement
interventions to reduce the risk of polypharmacy and other relevant medication-related
issues in the Medicaid population.
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We also found that individual characteristics such as being older, being female, and having
more chronic conditions were significantly correlated with polypharmacy, consistent with
the previous literature.2,4,5,25 In particular, we found that polypharmacy was not only related
to the number of chronic conditions, but also associated with different types of chronic
conditions. We found that patients with physical conditions were more likely to have
polypharmacy than those with mental conditions. This finding may be partially a result of
our measurement of polypharmacy, which only assessed different drug classes but not within
drug classes. Within-drug-class polypharmacy is not uncommon in mental condition
management; therefore, our definition may to some extent underestimate polypharmacy
burden in this population. Nevertheless, it is worthwhile for future research to further
investigate the impacts of different types and combinations of chronic conditions on
polypharmacy, inappropriate medication use, and medication regimen complexity. It is also
interesting in our results that about 5% of the individuals without any chronic disease
included in our study had polypharmacy, which may represent the population who used
medications for chronic diseases not included in this study, acute diseases, disease
prevention purposes, and/or unclear indications.
Additionally, for county-level characteristics, we found that lower educational level was
associated with polypharmacy, which was also reflected in the “hot spots” of polypharmacy
identified in our spatial analysis. Further research may need to confirm the influence of
individual educational level, patient knowledge about medications, and health literacy on
polypharmacy, which may also suggest important targets for developing interventions to
address these issues.
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Several limitations to this study should be noted. First, the cross-sectional design of this
study in 1 year made it difficult to infer causality. We did not measure the temporal
relationship between polypharmacy and health care use or nondrug medical expenditures in
this study, which warrants further research. Second, by our new definition, we only assessed
polypharmacy from different drug classes but not within-drug-class polypharmacy. For
instance, patients may take multiple antipsychotic drugs, but according to our definition,
they are only considered to be taking 1 drug class. Third, our approach may not fully capture
early refill issues or patients’ real medication-taking behaviors. Fourth, because the data did
not contain the accurate indications for the drug used or detailed clinical information, we
cannot differentiate between appropriate and inappropriate polypharmacy. Therefore, the
next step for this research will be to further explore inappropriate polypharmacy in this
population. Finally, caution is required when generalizing the study findings. In particular,
the impact of moving from FFS to managed care in WV Medicaid on polypharmacy is still
not clear and warrants further research. But the approach for assessing the prevalence and
geographic variations of polypharmacy established in this study may be applied to other
populations or geographic regions by using claims data.

Conclusions
Polypharmacy was highly prevalent among WV Medicaid FFS beneficiaries and was
associated with substantial health care use and expenditures. Future research is warranted to
explore inappropriate polypharmacy as well as these issues in the WV Medicaid managed
care population. The clustering of high prevalence of polypharmacy in southern WV may
suggest targeted strategies to improve medication use and reduce polypharmacy burden and
the risks of iatrogenesis in these areas.
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Flowchart for obtaining the final study population.

Appendix B
List of Chronic Conditions.
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Physical condition

Hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias,
hyperlipidemia, stroke, arthritis, asthma, cancer, chronic kidney disease, chronic
obstructive pulmonary disease, diabetes, hepatitis, HIV, osteoporosis

Mental condition

Depression, schizophrenia, substance abuse, anxiety or posttraumatic stress disorder,
and bipolar disorder

Physical and mental
condition

Dementia
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Figure 1.
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County-level polypharmacy rate and geographic variations among West Virginia Medicaid
beneficiaries. A. The choropleth map displays the aggregated county-level of polypharmacy
rates in WV. The county-level polypharmacy rates ranged from 31.2% to 54.4%. B. The
univariate local indicators of spatial association (LISA) method was used to help identify 4
types of spatial patterns: (1) low-low cluster (blue); (2) high-high cluster (red); (3) low-high
outlier (purple); and (4) high-low outlier (pink). A high-high cluster indicates a county with
an above-average prevalence surrounded by counties with above-average prevalence,
whereas a low-low cluster refers to a county with a below-average rate surrounded by
counties with below-average rates. As shown in the figure, we identified a large and clear
high-high cluster of polypharmacy in southern WV, which included 11 counties.
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Resources Files, and ARC Data Reports: Comparison Between Those With Polypharmacy and Those Without Polypharmacy.a

Description of the Study Population (18–64 Years Old) With Fee-for-Service Medicaid, Linked 2010 WV Medicaid Claim Database, Area Health

Author Manuscript

Table 1
Feng et al.
Page 13

19058
8473

None

22.6%

50.7%

26.7%

3556
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4818

n

21.2%

50.1%

28.7%

Percentage

4917
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5221
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2.1

Number of ED visits
8071.4

Number of outpatient visits

Nondrug medical costs (dollars)

0.3
27.3

Number of inpatient visits

2.2

SD

9588

Quartile 4 [21.7%, 38.1%]

Number of chronic conditions

25.5%

8581

18028.6

4.4

36.4

0.9

1.8

22.8%

9763

26.0%

25.7%

Quartile 3 [19.2%, 21.6%]

9638

Quartile 2 [13.3%, 19.1%]

Quartile 1 [8.9%, 13.2%]b
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2.4

36.4

0.4

3.1

Mean

4711
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3865

20742.3
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40.0

1.1

1.9
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28.1%

23.9%
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23.1%

5801.7

1.8

20

0.2

1.38

Mean

4877

4564

5586

5773

Abbreviations: ARC, Appalachian Regional Commission; ED, emergency department; WV, West Virginia.

15122.0
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31.4

0.6

1.4

SD

23.4%

21.9%

26.9%

27.8%

23.6%

51.3%

25.1%

Percentage

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

P Value

b
Quartile 1 has the highest education level as compared with other quartiles.

2010 only. P values were based on χ2 tests for categorical variables and t-tests for the continuous variables.

Based on 37570 adults (aged 18–64 years) who were continuously enrolled in fee-for-service Medicaid in both 2009 and 2010 and used either inpatient or outpatient services paid by Medicaid. Chronic
conditions and the number of chronic conditions were identified in the year 2009. The number of visits to ED, inpatient visits, and outpatient visits as well as the nondrug medical costs were measured in

a

n

The percentage of residents aged 25 years and older with less than a high school diploma (at the county level)

10039

Partial
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Whole county

Percentage

Author Manuscript
n

No Polypharmacy

Author Manuscript
With Poly pharmacy

Author Manuscript

All
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Factors Associated With Polypharmacy Among West Virginia Medicaid Beneficiaries: Using Multilevel
Logistic Regression (n = 37570).
Odds Ratio (95% CI)a

Variables
Age group
18–24

Reference

25–34

1.33 (1.14, 1.56)**

35–44

2.50 (2.16, 2.90)**

45–54

3.90 (3.38, 4.51)**

55–64

5.26 (4.54, 6.09)**

Sex
1.46 (1.39, 1.54)**

Female

Author Manuscript

Male

Reference

Medicaid eligibility pathway
Cash assistance

1.33 (1.16, 1.53)**

Medical need

1.51 (1.27, 1.78)**

Other

Reference

Number of chronic conditions

1.62 (1.58, 1.65)**

Presence of chronic conditions
Physical conditions only

1.98 (1.84, 2.14)**

Mental conditions only

Reference

Both physical and mental conditions

1.73 (1.59, 1.88)**

Without any chronic conditions included

0.87 (0.79, 0.97)**

Author Manuscript

County-level metropolitan status
Yes

1.00 (0.93, 1.32)

No

Reference

County-level economic status
Distressed

0.91 (0.75, 1.10)

Not distressed

Reference

Health professional shortage area for primary care doctors
Yes

1.07 (0.93, 1.22)

No

Reference

The percentage of residents 25 years and older with less than a high school diploma (at the county level

Author Manuscript

Quantile 1 [ 8.9%, 13.2%]

Reference

Quantile 2 [13.3%, 19.1%]

1.11 (0.93, 1.32)

Quantile 3 [19.2%, 21.6%]

1.22 (1.02, 1.45)*

Quantile 4 [21.7%, 38.1%]

1.44 (1.16, 1.78)**

Random effect
County-level variance

Estimate
0.024

a**

P < 0.01;
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*

0.01 < P < 0.05.
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Table 3
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Health Care Use and Expenditures Among Adults With Fee-for-Service Medicaid, Linked 2010 West Virginia
Medicaid Claim Database, the Area Health Resources Files, and the ARC Data Reports (n = 37 570).a
With Polypharmacy Versus No Polypharmacy
Number of emergency room visits
1.18 (1.13, 1.24)**

AOR (95% CI)
Number of inpatient visits

1.78 (1.67, 1.90)**

AOR (95% CI)
Number of outpatient visits
Incidence rate ratio (95% CI)

1.69 (1.66, 1.73)**

Nondrug costs
Coefficient (95% CI)

0.69 (0.64, 0.74)**

Author Manuscript

Abbreviations: AOR, adjusted odds ratio; ARC, Appalachian Regional Commission.

a

The results were adjusted by age groups, Medicaid eligibility pathway, sex, presence of chronic conditions, county-level metropolitan status, and
county-level economic status.

**

P < 0.01;

*

0.01 ≤ P < 0.05.
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